Three Abstracts That May Shape the Future of RA Treatment Save

Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an impact on our practice?

Here is my selection of 3 abstracts presented at EULAR 2026 that identify therapeutic strategies that are well worth keeping on our radar.

In abstract OP0202, Graf and colleagues present results from the phase 2b RENOIR trial evaluating rosnilimab, a monoclonal antibody that selectively depletes pathogenic PD-1high T-cell populations, including peripheral helper T cells (Tph), follicular helper T cells (Tfh), and effector T cells. These cell subsets have increasingly been implicated in RA pathogenesis and may act upstream of several established inflammatory pathways. In a cohort of 424 patients with active seropositive RA, including many with prior biologic exposure, all doses of rosnilimab achieved significant improvements in DAS28-CRP compared with placebo at week 12. Clinical responses continued to improve through week 28, with a substantial proportion of patients maintaining low disease activity even after treatment discontinuation. Importantly, safety signals were reassuring, with low rates of serious infections and no clear dose-dependent toxicity. These findings provide clinical proof-of-concept that selective depletion of pathogenic T-cell populations may represent a novel therapeutic strategy in RA.

In abstract OP0205, Pascart and colleagues address a common clinical dilemma: which mechanism of action should be selected after failure of a first biologic or targeted therapy? In the SUNSTAR trial, patients with active RA and inadequate response to one or two prior b/tsDMARDs were randomized to receive subcutaneous tocilizumab or abatacept. While the primary endpoint of superiority for CDAI improvement at week 26 was not met, tocilizumab demonstrated a significantly higher composite response rate incorporating treatment persistence, low disease activity, limited glucocorticoid use, and absence of intra-articular steroid injections. Treatment persistence at one year also favoured tocilizumab. Although the results do not establish clear superiority, they provide valuable head-to-head evidence supporting IL-6 inhibition as a particularly effective option following previous targeted therapy failure.

Finally, in abstract OP0209, McInnes and colleagues present results from the SPECIFI-RA trial evaluating balinatunfib, an oral small molecule designed to selectively inhibit TNF receptor 1 (TNFR1) signalling while preserving TNFR2-mediated pathways involved in immune regulation and homeostasis. This approach aims to retain the efficacy of TNF blockade while potentially avoiding some limitations associated with conventional anti-TNF therapies. Although the study did not meet its primary endpoint of ACR20 superiority over placebo, the 200 mg once-daily dose demonstrated encouraging signals in more stringent outcomes, including ACR50, ACR70, and low disease activity rates. In addition, reductions in circulating IL-6 levels provided evidence of biological target engagement. While further development is needed, these data suggest that selective TNFR1 inhibition remains a biologically attractive strategy worthy of continued investigation.

Together, these abstracts highlight the multiple avenues through which RA treatment continues to evolve. From novel T-cell-directed therapies and selective cytokine receptor inhibition to head-to-head comparisons of established biologics, the field is increasingly focused on improving outcomes through both innovation and refinement of existing strategies. As always, the challenge will be determining which of these advances ultimately translate into meaningful changes in routine clinical practice.